All In Biotech

Drug Trial Radar · NCT07033494

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Jul 16, 2025

Primary completion

Apr 30, 2029

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

Conditions

  • Early Alzheimer's Disease

Interventions

  • MK-2214Biological

    IV infusion

  • PlaceboDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Base Period: Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr)Time frame: Baseline, up to approximately 23 months
  2. Base Period: Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 26 months
  3. Base Period: Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 23 months

Locations

80 sites in 11 countries. Site status is shown where the registry gives one.

  • Irvine Clinical Research ( Site 1041)

    Irvine, California · Recruiting

  • Healthy Brain Clinic ( Site 1005)

    Long Beach, California · Recruiting

  • Inglewood Clinical ( Site 1062)

    Los Angeles, California · Recruiting

  • Anderson Clinical Research ( Site 1024)

    Redlands, California · Recruiting

  • UCSF Memory and Aging Center ( Site 1031)

    San Francisco, California · Recruiting

  • Syrentis Clinical Research ( Site 1001)

    Santa Ana, California · Recruiting

  • Yale University, Alzheimer's Disease Research Unit ( Site 1059)

    New Haven, Connecticut · Recruiting

  • JEM Research Institute ( Site 1046)

    Atlantis, Florida · Recruiting

  • Neuropsychiatric Research Center of Southwest Florida ( Site 1003)

    Fort Myers, Florida · Recruiting

  • K2 Medical Research ( Site 1047)

    Maitland, Florida · Recruiting

  • ClinCloud LLC ( Site 1039)

    Melbourne, Florida · Recruiting

  • Indago Research and Health Center Inc ( Site 1044)

    Miami Lakes, Florida · Recruiting

  • Aqualane Clinical Research ( Site 1035)

    Naples, Florida · Recruiting

  • Suncoast Clinical Research ( Site 1007)

    New Port Richey, Florida · Recruiting

  • Renstar Medical Research ( Site 1012)

    Ocala, Florida · Recruiting

  • Charter Research - Orlando ( Site 1051)

    Orlando, Florida · Recruiting

  • Axiom Brain Health ( Site 1029)

    Tampa, Florida · Recruiting

  • K2 Medical Research ( Site 1020)

    Tampa, Florida · Recruiting

  • Charter Research - Lady Lake ( Site 1019)

    The Villages, Florida · Recruiting

  • Conquest Research LLC ( Site 1053)

    Winter Park, Florida · Recruiting

  • CenExel iResearch, LLC ( Site 1015)

    Decatur, Georgia · Recruiting

  • Alexian Brothers Medical Center-Neurosciences ( Site 1017)

    Elk Grove Village, Illinois · Recruiting

  • Boston Center for Memory ( Site 1008)

    Newton, Massachusetts · Recruiting

  • Clinical Research Professionals ( Site 1004)

    Chesterfield, Missouri · Completed

  • CenExel- AMRI ( Site 1018)

    Marlton, New Jersey · Recruiting

  • The Cognitive and Research Center of New Jersey - Ridgewood ( Site 1064)

    Ridgewood, New Jersey · Recruiting

  • The Cognitive and Research Center of NJ ( Site 1057)

    Springfield, New Jersey · Recruiting

  • Alzheimer Disease Research Center (ADRC) ( Site 1000)

    Albany, New York · Recruiting

  • Mid Hudson Medical Research ( Site 1050)

    New Windsor, New York · Recruiting

  • Basil Clinical ( Site 1065)

    Queens, New York · Recruiting

  • AMC Research, LLC ( Site 1006)

    Matthews, North Carolina · Recruiting

  • Insight Clinical Trials ( Site 1011)

    Independence, Ohio · Recruiting

  • Neuro-Behavioral Clinical Research ( Site 1028)

    North Canton, Ohio · Recruiting

  • Flourish Research ( Site 1048)

    Plymouth Meeting, Pennsylvania · Recruiting

  • Gadolin Research ( Site 1032)

    Beaumont, Texas · Recruiting

  • Horizon Clinical Research Center - Houston ( Site 1026)

    Cypress, Texas · Recruiting

  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) ( Site 0400)

    Caba, Argentina · Recruiting

  • Organizacion Medica de Investigacion ( Site 0401)

    Ciudad de Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0404)

    Ciudad de Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Southern Neurology ( Site 0306)

    Kogarah, New South Wales, Australia · Recruiting

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.